Heart Test Laboratories Inc. Common Stock (HSCS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Heart Test Laboratories Inc. Common Stock stock (HSCS) is currently trading at $2.43. Heart Test Laboratories Inc. Common Stock PS ratio (Price-to-Sales) is 934.87. Analyst consensus price target for HSCS is $10.60. WallStSmart rates HSCS as Sell.
- HSCS PE ratio analysis and historical PE chart
- HSCS PS ratio (Price-to-Sales) history and trend
- HSCS intrinsic value — DCF, Graham Number, EPV models
- HSCS stock price prediction 2025 2026 2027 2028 2029 2030
- HSCS fair value vs current price
- HSCS insider transactions and insider buying
- Is HSCS undervalued or overvalued?
- Heart Test Laboratories Inc. Common Stock financial analysis — revenue, earnings, cash flow
- HSCS Piotroski F-Score and Altman Z-Score
- HSCS analyst price target and Smart Rating
Heart Test Laboratories Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Heart Test Laboratories Inc. Common Stock (HSCS) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Heart Test Laboratories Inc. Common Stock (HSCS) Key Strengths (1)
Revenue surging 654.00% year-over-year
Supporting Valuation Data
Heart Test Laboratories Inc. Common Stock (HSCS) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 934.9x annual revenue
Very low institutional interest at 6.21%
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 3.2x book value
Supporting Valuation Data
Heart Test Laboratories Inc. Common Stock (HSCS) Detailed Analysis Report
Overall Assessment
This company scores 21/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 654.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (934.87), Price/Book (3.22) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -382.30%, Operating Margin at -89940.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -382.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 654.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HSCS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HSCS's Price-to-Sales ratio of 934.87x sits near its historical average of 961.3x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 8% below its historical high of 1021.4x set in Feb 2026, and 0% above its historical low of 934.87x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Heart Test Laboratories Inc. Common Stock (HSCS) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Heart Test Laboratories Inc. Common Stock is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 8,670 with 654% growth year-over-year.
Key Findings
Revenue growing at 654% YoY, reaching 8,670. This pace significantly outperforms most MEDICAL DEVICES peers.
Debt-to-equity ratio of 0.21 indicates a conservative balance sheet with 2M in cash.
Free cash flow is -11M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Heart Test Laboratories Inc. Common Stock maintain 654%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.54, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Heart Test Laboratories Inc. Common Stock.
Bottom Line
Heart Test Laboratories Inc. Common Stock is a high-conviction growth story with revenue accelerating at 654% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Heart Test Laboratories Inc. Common Stock(HSCS)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company is headquartered in Southlake, Texas.